Intestinal Ischemia Biomarker in Patients With Chronic Mesenteric Ischemia
Recruiting · NCT06468774 · Observational (researchers observe without assigning treatment) · Lead sponsor: Oslo University Hospital
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
Plasma Alpha glutathione S transferase (Alpha GST) has been previously demonstrated to be raised in patients with chronic mesenteric ischemia (CMI) caused by atherosclerosis and in patients with median arcuate ligament syndrome (MALS). Raised plasma level of Alpha GST has been demonstrated to decrease or normalize after surgical treatment of patients with CMI and MALS as compared with healthy individuals. This study compares the plasma Alpha GST in patients with CMI and MALS with those with 1-Morbus Crohn, 2-Gallstone disease, and age-matched healthy individuals. Besides, changes in the health-related quality of life (QoL) will be investigated in the study individuals.
Who can take part
Inclusion criteria
- Above 18 years and has given informed written consent for treatment and study participation
- For the patient groups :
- Group 1: Has CTA or ultrasound diagnosed MALS and is scheduled operative treatment.
- Group 2: Has CTA or ultrasound diagnosed CMI and is scheduled operative or endovascular treatment.
- For the control group:
- Group 3- Has ultrasound based diagnosis of cholelithiasis and is scheduled for cholecystectomy.
- Group 4- Has established Mb Crohn diagnosis and under gastric lab follow-up. Group 5- Young healthy blood donors of mean age 45 years and has excluded MALS or CMi with ultrasound.
- Group 6- Healthy blood donors of mean age 70 years and has excluded MALS or CMi with ultrasound.
Exclusion criteria
- Age less than 18 years Has nor given written consent.
Where it is running
1 location listed.
- Department of vascular surgery, Oslo University Hospital - Oslo, Oslo, Norway